Clinical trials
Observational Aspergillosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 4 |
| 2021 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Unknown status | 9 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heidelberg University | 3 |
| Merck Sharp & Dohme LLC | 2 |
| Pfizer | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Assiut University | 1 |
| Astellas Pharma China, Inc. | 1 |
| Astellas Pharma Singapore Pte. Ltd. | 1 |
| Catholic University of the Sacred Heart | 1 |
| Erasmus Medical Center | 1 |
| European Society for Blood and Marrow Transplantation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aspergillosis | 35 |
| Candidiasis | 8 |
| Invasive Fungal Infections | 6 |
| Mycoses | 6 |
| COVID-19 | 4 |
| Mucormycosis | 4 |
| Influenza, Human | 3 |
| Candidemia | 2 |
| Candidiasis, Invasive | 2 |
| Pneumonia, Pneumocystis | 2 |
Trials
Showing 26 to 35 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.